https://www.live-feeds.com/feed/why-amgen-stock-is-getting-hit-by-a-novartis-trial-setbackContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/why-amgen-stock-is-getting-hit-by-a-novartis-trial-setbackhttps://www.live-feeds.com/feed/why-amgen-stock-is-getting-hit-by-a-novartis-trial-setback#u63717Thu, 10 Sep 2026 08:16:34 +0000Amgen shares experienced their worst drop in more than two decades, dragging down the Dow after an experimental cardiovascular drug from Novartis failed a major study. The setback sent shockwaves through the medical and financial communities, raising doubts about the broader multibillion-dollar race for similar cholesterol and heart treatments. Cardiologists and market analysts expressed surprise at the failure, which immediately rattled the market for rival therapies and heavily weighed on overall index performance. Investors quickly repriced expectations across the sector as confidence in co